MBD1: A Protein Involved in Many Body Processes and Potential Drug Targets

Target Name: MBD1

NCBI ID: G4152

MBD1

MBD1: A Protein Involved in Many Body Processes and Potential Drug Targets

MBD1 (CXXC-type zinc finger protein 3) is a protein that is expressed in a variety of tissues throughout the body, including the brain, heart, and lungs. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues.

One of the unique features of MBD1 is its structure. It is a zinc finger protein, which means that it contains a zinc atom that is held by a finger-like structure. This finger-like structure is composed of multiple amino acids that are held together in a specific sequence. The sequence of these amino acids is important, as it determines the structure and function of the protein.

MBD1 is also involved in many different processes in the body. For example, it is involved in the development and maintenance of tissues, such as muscles and bones. It is also involved in cell signaling, as it can interact with a variety of signaling molecules.

One of the reasons that MBD1 is thought to be a drug target is its involvement in cancer. Many studies have shown that MBD1 is often overexpressed in cancer cells, which can lead to the development of cancer. Additionally, MBD1 has been shown to promote the growth and survival of cancer cells, which further supports its role as a drug target.

Another potential drug target for MBD1 is its involvement in autoimmune diseases. Many studies have shown that MBD1 is often overexpressed in autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. This suggests that MBD1 may play a role in the development and progression of these diseases.

MBD1 is also involved in the development and maintenance of the nervous system. It is a key regulator of neural development and function, and is involved in the production of many important neurotransmitters. This suggests that MBD1 may be a potential drug target for conditions such as Alzheimer's disease and Parkinson's disease.

In addition to its potential drug targets, MBD1 is also a potential biomarker. Many studies have shown that MBD1 is often overexpressed in a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative diseases. This suggests that MBD1 may be a useful biomarker for these conditions.

Overall, MBD1 is a protein that is involved in many important processes in the body. Its structure and function make it a potential drug target, and its involvement in cancer and autoimmune diseases makes it a potential biomarker. Further research is needed to fully understand the role of MBD1 in these processes and to develop effective treatments.

Protein Name: Methyl-CpG Binding Domain Protein 1

Functions: Transcriptional repressor that binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides. Binding is abolished by the presence of 7-mG that is produced by DNA damage by methylmethanesulfonate (MMS). Acts as transcriptional repressor and plays a role in gene silencing by recruiting ATF7IP, which in turn recruits factors such as the histone methyltransferase SETDB1. Probably forms a complex with SETDB1 and ATF7IP that represses transcription and couples DNA methylation and histone 'Lys-9' trimethylation. Isoform 1 and isoform 2 can also repress transcription from unmethylated promoters

The "MBD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MBD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets